US 5972619

I'll search for authoritative information on this specific patent number, including any 2026 CAFC docket activity.

The 2026 CAFC query returned no relevant hits (only unrelated Australian patent journal content). Let me dig for the actual claim set of '619 and its litigation history.

Let me pull the actual claim set and front-page data for '619 directly.

US 5,972,619 — Analyst Summary

1. Scope and search method (and its limits)

I ran open web searches keyed to the literal string "5972619" / "5,972,619" plus USPTO-republishing sites, Google Patents, Justia Patent Profiles, Unified Patents, CourtListener, and general docket-web sources, including a targeted query for any 2026 CAFC activity.

Two honest limitations up front:

• I do not have direct API access to USPTO PatentCenter/PAIR or to the Federal Circuit's docket system (PACER/CM-ECF). "Searching the USPTO database and CAFC 2026 dockets" here means searching indexed public mirrors of those records, which is weaker than a native docket query.
• The full patent text supplied to me for '619 ends before the claims. I therefore could not verify the '619 claim set from an authoritative copy in this session (details in §4).

2. Bibliographic summary — US 5,972,619

Sources: https://patents.google.com/patent/US5972619/en; https://idiyas.com/patent/badge/5972619.

3. Abstract (as published)

"The conditions under which oligonucleotide probes hybridize preferentially with entirely complementary and homologous nucleic acid targets are described. Using these hybridization conditions, overlapping oligonucleotide probes associate with a target nucleic acid. Following washes, positive hybridization signals are used to assemble the sequence of a given nucleic acid fragment. Representative target nucleic acids are applied as dots. Up to 100,000 probes of the type (A,T,C,G)(A,T,C,G)N8(A,T,C,G) are used to determine sequence information by simultaneous hybridization with nucleic acid molecules bound to a filter. Additional hybridization conditions are provided that allow stringent hybridization of 6‑10 nucleotide long oligomers which extends the utility of the invention. A computer process determines the information sequence of the target nucleic acid which can include targets with the complexity of mammalian genomes. Sequence generation can be obtained for a large complex mammalian genome in a single process."

The specification is the classic Drmanac/Crkvenjakov SBH disclosure: low‑temperature short‑oligonucleotide hybridization with end‑mismatch discrimination down to 6‑mers; "dissolve the target into all constituent N‑mers and reassemble by maximal non‑identical (N‑1) overlap"; subfragments/informative fragments generated at repeated (k‑1) branch points; two‑library (basic + ordering) strategy with pooled fragments; and an appendix algorithm (QuickBasic, MS‑DOS) handling false‑positive/false‑negative k‑tuples, misconnected subfragments, and unambiguous connection rules.

4. Independent claims — plain-language overview (with explicit uncertainty)

Important caveat: I could not retrieve an authoritative copy of the '619 claim set. The supplied full text stops mid‑sentence in §5.2, before the claims. What follows is (a) what the patent's own Summary and Appendix describe as the inventive contribution, and (b) the closest authoritative analogue I could find — the claims of the sibling U.S. patent 6,316,191 (Appl. 09/205,865, filed Dec. 4, 1998, issued Nov. 13, 2001, same title, same specification, same inventors, same assignee, same family). Do not treat the '191 text below as verbatim '619 claim language.

What the title/Summary indicate the '619 claims are directed to: a computer‑implemented method of analyzing hybridization data — the "computer process determines the information sequence" element that distinguishes this continuation from its parent sequencing patents ('231, '464, '940).

Closest analogue — US 6,316,191 claims 1–6 (https://uspto.report/patent/grant/6316191):

• Claim 1 — A method of analyzing a target nucleic acid sequence: obtain a plurality of H values, each = the extent of hybridization of an oligonucleotide probe to a sequence including the target, with the probes differing from one another by at least a single base; compare the H values to each other to analyze the target. (In plain terms: compare raw hybridization signal strengths across related probes to infer something about the target.)
• Claim 2 — Same, but the analysis is by calculating a "D value" from the ratio of a higher H value to a lower H value (i.e., a discrimination ratio between a better‑ and worse‑matching probe).
• Claim 3 — Same idea using two sets of H values: one from a control/reference nucleic acid and one from the target, then comparing at least one value from each set.
• Claim 4 — Same idea using a statistical data set compiled from a plurality of experiments on a control sequence, compared against the target's H values.
• Claim 5 — The method of any of claims 1–4 performed on a computer.
• Claim 6 — The method of claim 5 wherein the oligonucleotide probes are in an array.

Reasoned inference (flagged as inference, not verified): because '619 is the earlier‑filed, earlier‑issuing sibling in the same family with the same title and the same "computer‑aided" framing, its independent claims most likely recite computer‑implemented hybridization‑data analysis in the same family of concepts — comparing measured hybridization extents (H values), computing discrimination ratios of higher‑to‑lower signal (D values), comparing target data against control or multi‑experiment statistical data, and probe arrays — with the computer limitation supplying the novelty over the parent patents. I cannot confirm the exact claim wording, count, or scope, and I may be wrong about it.

Conflation warning: several aggregator pages mix '619 into unrelated claim sets. The 35‑claim set about "inputting a plurality of probe intensities… intensity ratio method… ViewSeq…" belongs to US 6,607,887 / publication 2002/0012925 (Chee, Affymetrix) — a different patent — not to '619. Do not attribute those claims to '619.

5. Litigation record — and the 2026 CAFC question

No 2026 CAFC docket activity for '619 was found. My CAFC‑targeted query returned only unrelated Australian patent‑office journal content. Given the patent is recorded as expired 2008‑03‑30 and was subject to a comprehensive 2001 settlement (below), the absence of 2026 appellate activity is consistent, though I cannot rule out an unindexed filing. Treat this as "no evidence found," not as "confirmed none."

The well‑documented '619 litigation history:

1. Hyseq, Inc. v. Affymetrix, Inc. (N.D. Cal., Case No. C 97‑20188 RMW) — Hyseq sued Affymetrix for infringement beginning March 1997 (a complaint filed March 4, 1997 is described in Nature Biotechnology 15:406 (1997), which identifies Hyseq as formed to exploit the Drmanac/Crkvenjakov patents and describes the dispute over whether gene‑chip mutation detection is really "sequencing by hybridization"). Source: https://www.nature.com/articles/nbt0597-406a.pdf.
2. Affymetrix, Inc. v. Hyseq, Inc. (N.D. Cal., Case No. C 99‑21163 JF; consolidated with C 99‑21164 involving Synteni/Incyte) — reported at 132 F. Supp. 2d 1212 (N.D. Cal. 2001) (Judge Fogel), a Markman/claim‑construction ruling (e.g., construing "computer code" as reciting structure). Source: https://www.courtlistener.com/opinion/2457323/affymetrix-inc-v-hyseq-inc/summaries/.
3. Hyseq, Inc. v. Affymetrix, Inc. (N.D. Cal., Case No. C 00‑20050 RMW).
4. A secondary (Chinese‑language) litigation chronology indicates Hyseq asserted '619 against Affymetrix in a renewed round of the dispute (dated to Oct./Nov. 1999). This is a secondary source and I flag it as unverified.
5. Settlement, October 24, 2001 — the parties dismissed all three suits with prejudice and expressly acknowledged the validity and enforceability of Hyseq's U.S. Patent Nos. 5,202,231; 5,525,464; 5,695,940; 6,018,041; and 5,972,619. Hyseq contributed its SBH patents to a new subsidiary, Callida Genomics, Inc.; Affymetrix took an initial 10% equity and cross‑licenses followed (N‑Mer, Inc.). Sources: Affymetrix Form 8‑K dated Nov. 1, 2001 (https://capedge.com/filing/913077/0000912057-01-537335/AFFX-8K); https://contracts.justia.com/companies/arca-biopharma-inc-7676/contract/891682/.
6. Related interference No. 104,552 (Chee v. Drmanac) between Affymetrix's 5,795,716 / 5,974,164 and Hyseq Appl. 09/358,875 — resolved by the same settlement (Hyseq filed an abandonment of contest). Source: https://www.lawinsider.com/contracts/14u1Z4ttG4z.

So '619's documented enforcement life ran roughly 1997–2001 in the Northern District of California; I found no Federal Circuit appeal decision specific to '619, and no 2026 activity.

6. Explicit uncertainties

• '619's actual independent claims: not verified. My claim overview rests on the specification, the patent's stated purpose, and the claims of sibling US 6,316,191 — not on an authoritative transcription of '619.
• 2026 CAFC docket: no evidence found, but my access was indirect (public web indexes, not PACER/CM-ECF or USPTO PatentCenter).
• Expiration date (2008‑03‑30) and legal status ("Expired – Fee Related") are as listed by Google Patents; Google itself notes legal statuses are assumptions, not legal conclusions.
• Assignee chain (Hyseq → Callida Genomics → Nuvelo/Affymetrix security interests) is as recorded in assignment/security filings indexed by Google Patents; I did not verify the underlying recorded instruments.

I'll search for litigation involving US patent 5972619 specifically.

Let me search more specific litigation sources.

Found key leads. Let me dig deeper into the Hyseq v. Affymetrix case involving this patent.

Litigation Involving US Patent No. 5,972,619

Caveat up front: I was able to confirm that this patent (a Hyseq, Inc. patent titled "Computer-aided analysis system for sequencing by hybridization") was asserted in litigation, but I was unable to verify specific case numbers or docket details within the research steps available to me. I have flagged below exactly what is confirmed versus what needs verification against PACER/CourtListener. I am not fabricating case numbers.

1. Confirmed: The patent family has litigation

Google Patents' page for US 5,972,619 carries a "Family has litigation" flag, linking to the Darts-IP global litigation dataset for family ID 46248968:

• https://patents.google.com/patent/US5972619/en (see "Family has litigation" / Darts-IP link)

This confirms the patent is part of a family that has been litigated, but the flag alone does not give the case particulars.

2. Hyseq, Inc. v. Affymetrix, Inc. (N.D. Cal.) — '619 asserted by Hyseq against Affymetrix

This is the principal litigation I can tie specifically to US 5,972,619.

Supporting sources:

• A Taiwan academic/patent-study document (mmot.org.tw) provides a Hyseq–Affymetrix litigation timeline table stating: "1999.10.27 — ...Hyseq ... 第三次 '再利用當通過的 US 5,972,619 號專利再度控告專利侵權，並再次主張 Affymetrix 的 US 5,795,716 號專利無效" — i.e., after the Markman ruling, Hyseq for the third time asserted patent infringement, using its then-newly issued US 5,972,619, and again asserted that Affymetrix's US 5,795,716 patent was invalid. The same table records "2001.10.01 — Affymetrix 與 Hyseq 達成和解並取得商業授權" (Affymetrix and Hyseq reached a settlement and obtained a commercial license). Source: https://www.mmot.org.tw/uploads/603a0be0d9f24.pdf
• Hyseq's 10-K annual report (FY2001) states: "In October 2001, the Company entered into a settlement agreement with Affymetrix providing for the comprehensive settlement of a..." Source: http://getfilings.com/o0000891618-02-001598.html
• Earlier BioCentury coverage confirms Hyseq sued Affymetrix in the N.D. Cal., alleging infringement of Hyseq's SBH patents, and that there were two 1997 suits plus later filings. Source: https://www.biocentury.com/article/[141953](/patent/141953)/... and https://www.biocentury.com/article/56155/...

3. Affymetrix, Inc. v. Hyseq, Inc. (mirror/consolidated litigation)

Sources:

• CourtListener: https://www.courtlistener.com/opinion/[2457323](/patent/2457323)/affymetrix-inc-v-hyseq-inc/
• Casetext: http://g.casetext.com/case/affymetrix-inc-v-hyseq-inc
• Studicata case summary: https://www.studicata.com/summaries/united-states-district-court-northern-district-of-california/affymetrix-inc-v-hyseq-inc-2001-h3wyrd/

Note: Affymetrix's 1999 SEC filing also references Hyseq's suits and states that Affymetrix filed its own suit in 1998 in the Northern District of California. Source: https://capedge.com/filing/s3-content/0001047469-99-032354/1

4. Ownership history (relevant to standing/renumbering)

Google Patents records reassignments of the '619 family:

• 1998-10-22 — Assigned to Hyseq, Inc. (original assignee).
• 2004-12-14 — Reassigned to Nuvelo, Inc. and Affymetrix, Inc. (security agreement; assignor Callida Genomics, Inc.).

Source: https://patents.google.com/patent/US5972619/en (reassignment entries).

This is consistent with the Affymetrix–Hyseq/Callida relationship that followed the 2001 settlement.

5. What I could NOT confirm (do not treat as established)

• Specific district-court case numbers for the Hyseq-v.-Affymetrix actions asserting the '619 (e.g., a docket number). I did not locate a verified docket number in this session. This should be checked directly on PACER and CourtListener.
• Whether the '619 was ever asserted against any party other than Affymetrix (e.g., Incyte, Synteni). Affymetrix's filings list Hyseq/Incyte/Synteni as adverse parties in the broader SBH patent war, but I did not confirm the '619 itself was asserted against them.
• Any post-2001 litigation on the '619 (the patent was subject to a terminal disclaimer / anticipated expiration date of 2008-03-30 per Google Patents, and is now Expired – Fee Related). No later litigation surfaced in my searches.

Bottom line

Yes — US 5,972,619 was litigated. It was asserted by Hyseq, Inc. against Affymetrix, Inc. in the U.S. District Court for the Northern District of California, in a third Hyseq action filed on or about October 27, 1999, alongside Hyseq's related SBH patents (5,202,231; 5,525,464; 5,695,940). That litigation, together with Affymetrix's consolidated counter-suits against Hyseq (and Incyte) (Affymetrix, Inc. v. Hyseq, Inc., 132 F. Supp. 2d 1211 (N.D. Cal. 2001)), was resolved by a comprehensive settlement and license between Affymetrix and Hyseq announced in October 2001.

To obtain the exact case numbers, I recommend pulling the Hyseq-v.-Affymetrix N.D. Cal. dockets (1997–2001) directly from PACER and cross-checking CourtListener and the Unified Patents litigation portal (https://portal.unifiedpatents.com/litigation/caselist), which I was unable to query directly within my search budget here.

I'll start by checking the structured data default against live sources.

PTAB / AIA Trial Report — US 5,972,619

"Computer-aided analysis system for sequencing by hybridization"
Inventors: Radoje T. Drmanac; Radomir B. Crkvenjakov • Original assignee: Hyseq Inc.
Filing date 1998-10-22 • Grant date 1999-10-26 • Priority 1987-04-01 (YU 570/87)
Source of record: https://patents.google.com/patent/US5972619/en

Proceedings overview

Total AIA trial proceedings on file: 0 (0 IPR, 0 PGR, 0 CBM) — zero active, zero claims invalidated, zero claims sustained, zero settled, zero institution denials; the USPTO Open Data Portal returns no AIA trial proceedings for this patent, and independent web searching of PTAB and Federal Circuit material surfaced none. The bottom-line defensive posture is therefore not "hardened by surviving IPRs" but "moot by expiration plus a 2001 global settlement": US 5,972,619 reached its anticipated expiration on 2008-03-30, roughly four years before the first AIA petition could be filed (AIA trials became available 2012-09-16), so no AIA proceeding was ever filed against it — and none is worth filing, because the § 286 six-year damages lookback closed around 2014.

Because there are no AIA proceedings to report, the sections below cover (a) the pre-AIA proceedings that are frequently mislabeled as "PTAB activity," and (b) what that history means for a defendant today.

No AIA trial proceedings — verified negative

Caveat on confidence: the ODP list is canonical and I treat the count as zero. My independent searching corroborates zero, but I cannot prove a universal negative from search alone; if you need belt-and-suspenders certainty, run a PTAB E2E party-name search for "Hyseq," "Nuvelo," "Callida Genomics," and "Affymetrix" and confirm no unindexed petition: https://e2e.uspto.gov/

Closest pre-AIA analogues (NOT AIA trials — do not cite these as IPRs)

Interference No. 104,552 — Chee v. Drmanac

• Type: Pre-AIA patent interference before the Board of Patent Appeals and Interferences (predecessor to the PTAB).
• Status: Terminated by abandonment of contest by Hyseq, as a component of the Affymetrix–Hyseq settlement. Source: Affymetrix Form 8-K, 2001-11-01: https://capedge.com/filing/[913077](/patent/913077)/0000912057-01-[537335](/patent/537335)/AFFX-8K
• Why it matters: This is the only USPTO contested proceeding involving the Drmanac/Crkvenjakov sequencing-by-hybridization family, and it ended in Hyseq conceding the priority contest rather than in a claim-canceling decision. No claims of the '619 were invalidated. An interference is not a validity adjudication, so it has no estoppel or claim-cancellation effect.

Affymetrix ↔ Hyseq district-court cluster (N.D. Cal.), 1997–2001

• Cases: Hyseq, Inc. v. Affymetrix, Inc., No. C 97-20188 RMW (ENE); Affymetrix, Inc. v. Hyseq, Inc., No. C 99-21163 JF; Hyseq, Inc. v. Affymetrix, Inc., No. C 00-20050 RMW (N.D. Cal., San Jose Div.).
• The '619's role: Hyseq filed the third suit on 1999-10-27, the day after the Markman hearing, asserting US 5,972,619 and again challenging the validity of Affymetrix's US 5,795,716.
• Resolution: Settlement Agreement entered 2001-10-24 (announced 2001-11-01). Terms per the 8-K and the public settlement text:
  • All three lawsuits dismissed with prejudice.
  • Both sides "acknowledged the validity and enforceability" of the asserted patents — Hyseq's US 5,202,231; 5,525,464; 5,695,940; 6,018,041; 5,972,619 — and Affymetrix's US 5,795,716; 5,744,305; 5,800,992.
  • Mutual releases and cross-licenses; Hyseq § 3.1 released Affymetrix and, notably, "any customers, agents and users of any of the Affymetrix Released Parties" for claims arising from "making, using, importing, selling, or offering to sell any Affymetrix microarray-related" products (settlement text: https://www.lawinsider.com/contracts/g6AKlqrMZ3S).
  • Affymetrix took a minority stake and options in Callida Genomics, the sequencing-by-hybridization joint venture.
• Sources: Affymetrix 8-K (above); Hyseq 10-K for FY2001, Item 3 Legal Proceedings: https://www.sec.gov/Archives/edgar/data/[907654](/patent/907654)/000089161802001598/f79510e10-k.htm ; contemporaneous trade coverage: https://www.nature.com/articles/nbt0597-406a.pdf
• Defensive value today: The "acknowledged validity and enforceability" language is a contractual admission that binds the parties — it is not a patentability determination and carries no stare decisis or estoppel effect against a non-party. Do not let opposing counsel characterize it as an adjudication.

Strategic summary

Which claims are canceled vs. sustained vs. untested. There is no PTAB Final Written Decision, so no claim of US 5,972,619 has been canceled, confirmed, or patentably adjudicated by the PTAB in any AIA trial. Every claim is "untested" in the AIA sense. What actually constrains the patent is the calendar: as a 1998-filed continuation claiming 1987/1988 priority, the patent was subject to a 20-year term measured from its earliest U.S. filing (Ser. No. 07/175,088, filed 1988-03-30), giving an anticipated expiration of 2008-03-30 per Google Patents, with legal status "Expired – Fee Related" (maintenance-fee lapse is a plausible additional off-ramp, given the 2004 Nuvelo/Affymetrix security agreement over Callida Genomics assets). Practically: the patent has been dead for over eighteen years, and the § 286 six-year back-damages window on any pre-expiration conduct effectively closed around 2014-03-30. If a demand letter today cites US 5,972,619, the right first response is a term/expiration objection, not an IPR petition.

Estoppel landscape. § 315(e)(2) estoppel is nonexistent here because there has never been an AIA petitioner — nobody is barred from any ground, and conversely no petitioner has locked in a winning invalidity theory you could borrow. Likewise there is no IPR FWD to which you could attach a collateral-estoppel or "reasonably could have raised" argument, and no IPR estoppel to worry about as a defendant. The only contractual constraint runs the other way and is confined to Affymetrix and its privity: the 2001 covenant not to sue, and the release running to Affymetrix microarray-product customers/users, is a genuine defense for a defendant who sourced accused product from Affymetrix (now part of Thermo Fisher) — but it covers claims existing as of the 2001 effective date and does not help an unrelated defendant accused of independent conduct.

Pattern signals. No repeat petitioner (there is no petitioner). No PTAB-to-CAFC appeal history for this patent — searches of PTAB decisions and Federal Circuit material returned nothing, and the only appellate-style activity in the family's history is the 2001 mutual dismissal and the abandoned interference. No defensive aggregator (Unified Patents, RPX, etc.) appears anywhere in the chain; the notable third-party involvement is the 2004 Nuvelo, Inc. / Affymetrix, Inc. security agreement over Callida Genomics assets, which is a corporate-finance event, not a validity challenge. Assertion history is a single burst: Hyseq (with Drmanac, Crkvenjakov, and CEO Lewis Gruber driving it) sued Affymetrix three times in 1997–1999 and then licensed rather than litigated.

Recommended next steps

1. Lead with expiration, not invalidity. For US 5,972,619 the dispositive fact is the 2008-03-30 anticipated expiration and "Expired – Fee Related" status shown at https://patents.google.com/patent/US5972619/en. Any demand letter asserting it today should be answered with (i) no enforceable term for post-2008-03-30 conduct, and (ii) § 286's six-year lookback having closed circa 2014 for any pre-expiration conduct — i.e., a damages claim is time-barred.
2. Demand the assertion basis before doing any prior-art work. If the letter-writer claims a longer term (e.g., "17 years from the 1999-10-26 grant" ≈ 2016-10-26), that theory collides with the URAA 20-year/earliest-filing measurement for this post-June-8-1995 continuation — get them to state their term calculation in writing. I did not retrieve the patent's full claim set in the truncated source text, so I am not asserting any claim numbers or claim count; pull the printed claims from the USPTO PatentCenter copy before responding on the merits.
3. If you are an Affymetrix/Thermo Fisher customer or a 1997–2001-era counterparty, invoke the 2001 settlement directly: dismissal with prejudice of all three N.D. Cal. cases, mutual releases, and the § 3.1 covenant not to sue running to Affymetrix's "customers, agents and users" for microarray-related products (settlement text: https://www.lawinsider.com/contracts/g6AKlqrMZ3S). Confidential terms (royalty, license scope, Callida equity) were redacted in the public version — treat them as confidential and do not characterize them further.
4. Do not bother filing an IPR. Although the Board will entertain a petition on an expired patent, there is no live infringement exposure to defend, no co-pending litigation posture to support a § 315(b) timing play, and the cost is unjustifiable. If you nonetheless need a paper record of invalidity, an ex parte reexamination reissue of the same art is the cheaper route — but note the same mootness point applies.
5. Confirm the negative on the record. Run PTAB E2E (https://e2e.uspto.gov/) party searches for Hyseq, Nuvelo, Callida Genomics, and Affymetrix against US 5,972,619 and its family members (notably US 5,525,464 and US 5,695,940, which are direct continuations in the same chain and were asserted in the 1997–2001 litigation). Those siblings could carry their own AIA-trial or reexamination history even though the '619 does not.

Flags on what I could not verify: (a) whether any unindexed or very recently filed petition exists that ODP has not yet ingested — treated as no; (b) the exact number and text of claims in US 5,972,619 — not retrieved in the available source text, so no claim-level statement is made; (c) whether the "Expired – Fee Related" status stems from maintenance-fee non-payment versus term expiry — both point to the same 2008 endpoint per Google Patents.

I'll research the assignment record for US 5972619 before drafting. Let me start with several parallel searches.

Let me search for the specific assignment records and litigation history.

I was able to retrieve the substantive ownership narrative and enforcement history, but not the reel/frame numbers or correspondent fields — those live only behind the Assignment Center's dynamic search, which my tools could not query directly. I flag that explicitly below rather than guessing.

Inventors

Notes on pattern:

• The parallel EP application in this family (EP 90107066.4, filed 1990-04-12, priority YU 767/89) names the Belgrade institute itself as applicant and the two inventors at Belgrade addresses — corroborating that the inventors' original employer was the Yugoslav institute, not Hyseq. The chain of title from that institute to Hyseq, Inc. is implied but not documented in any record I could retrieve; there is no findable instrument of transfer in the sources consulted.
• Unusual pattern (present): both inventors were Yugoslav-institute employees at the 1987 YU priority date and at the 1988 US parent filing, yet the issued US patent is assigned to a Sunnyvale, California company (Hyseq). A foreign-institute → US-startup assignment of this vintage with no recorded instrument is a genuine anomaly worth a chain-of-title check.
• Drmanac subsequently relocated to California and became the central figure at Hyseq/Callida/Complete Genomics; Crkvenjakov is not associated with the later US entities. That divergence is consistent with a founder-side IP contribution to Hyseq rather than a portfolio fire-sale — I do not see the "all inventors depart within 12 months of filing" pattern, because the inventors never appear as assignees in the first place.

Original assignee

Hyseq, Inc., Sunnyvale, CA — named as assignee on the face of US 5,972,619 (issued 1999-10-26).

• Business: genomics / sequencing-by-hybridization (SBH) tool and diagnostic development. Hyseq was formed ~1994 around the inventors' SBH work; it took a $2M NIST Advanced Technology Program award (1995–1997), IPO'd in 1997, and generated revenue largely from gene-screening collaborations (BASF, Chiron) rather than from a commercial SBH product.
• Did it ship a product embodying the claims? No — not in any meaningful commercial sense. Hyseq built the HyChip prototype (reported correct scoring on ~1M probes against HIV sequence, ~99.99% accuracy on its own benchmarks), but commercialization stalled after partner PerkinElmer/Applied Biosystems deprioritized the reader hardware. NIST's own retrospective describes the technology as not commercialized by project end.
• Current status: Dissolved/renamed. Hyseq acquired Variagenics and renamed itself Nuvelo, Inc. in 2003. Nuvelo subsequently merged with ARCA biopharma (2008–09). The SBH IP was carved out separately (see timeline).
• Status of the patent itself: USPTO legal status is Expired – Fee Related, with an anticipated expiration of 2008-03-30. It is unenforceable today for term reasons.

Assignment timeline

Important caveat on sourcing. I could not reach the Assignment Center's record viewer, so I do not have reel/frame numbers or the named correspondent of record. What follows is built from the Google Patents legal-events table for US5972619 (which mirrors the Assignment Center's abstract data), SEC filings (Hyseq/Nuvelo 10-K), and NIST/GenomeWeb reporting. Treat every "Reel/Frame not retrieved" line as unverified and requiring a manual look-up before it is relied on.

• 1998-10-22 / recorded 1998-10-22 — Reel/Frame not retrieved
  • Conveyance: Application filed / priority to US09/176,819 (not an assignment)
  • Assignor: n/a (applicant Hyseq, Inc.)
  • Assignee: Hyseq, Inc.
  • Correspondent: not retrieved
  • Context: internal prosecution event — continuation filing by the then-owner, not a transfer.
• 1999-10-26 — Reel/Frame not retrieved
  • Conveyance: Application granted / publication of US5972619A (not an assignment)
  • Assignor: n/a
  • Assignee: Hyseq, Inc.
  • Correspondent: not retrieved
  • Context: issuance to the original assignee.
• ~2001–2002 — no instrument retrieved
  • Conveyance: Internal reorganization / contribution to subsidiary (implied)
  • Assignor: Hyseq, Inc.
  • Assignee: Callida Genomics, Inc. (majority-owned subsidiary)
  • Correspondent: not retrieved
  • Context: internal reorg, not a sale. Per the Hyseq 10-K, Callida was formed in Oct 2001 to "focus on the development and commercialization of our SBH technology," and the NIST report states Callida "inherited all the intellectual property related to Hyseq's ATP-funded project." I could not locate a separately recorded assignment effecting this transfer; it may have occurred by capital contribution or merger without a standalone instrument, or the instrument was not indexed in the sources I could reach.
• 2003 — Reel/Frame not retrieved
  • Conveyance: Change of name (Hyseq, Inc. → Nuvelo, Inc.), following the Variagenics acquisition
  • Assignor: Hyseq, Inc.
  • Assignee: Nuvelo, Inc.
  • Correspondent: not retrieved
  • Context: change of name only — no change in beneficial ownership of the patent.
• 2004-12-14 / recorded 2004-12-14 — Reel/Frame not retrieved (this is the one assignment entry visible in Google Patents legal events; the recording predates reel/frame display in the summary I could access)
  • Conveyance: Security Agreement
  • Assignor: Callida Genomics, Inc.
  • Assignee: Nuvelo, Inc. and Affymetrix, Inc.
  • Correspondent: not retrieved
  • Context: collateralization / security interest, not an outright assignment of title. This is consistent with the Oct 2001 settlement architecture, under which Affymetrix loaned Hyseq $4M secured by the company's equity interest in Callida and took a ~10% equity stake in Callida with an option over N-Mer, Inc. A recorded security agreement names the secured parties as "assignees" in USPTO parlance but does not convey title. I found no evidence of foreclosure, so title appears to have remained with Callida.
• 2004 (late) — Reel/Frame not retrieved
  • Conveyance: Divestiture / buyback (reported, instrument not retrieved)
  • Assignor: Nuvelo, Inc.
  • Assignee: Radoje Drmanac (buying Callida back)
  • Correspondent: not retrieved
  • Context: fire-sale-adjacent divestiture of a non-core unit — Nuvelo "finally divested itself completely of Callida, which in turn was bought back by one of Hyseq's co-founders, Radoje Drmanac." This is a strategic exit, not a bankruptcy sale.
• 2008-03-30 — legal status Expired – Fee Related (anticipated expiration), not an assignment.
• 2006 onward (context only): Drmanac spun Complete Genomics out of Callida (March 2006); Complete Genomics was later acquired by BGI (2013). I have no recorded assignment moving US5972619 into Complete Genomics or BGI, and I will not assert one.

On correspondents: the assignment correspondents of record could not be retrieved, so the repeat-correspondent test below cannot be run. For context (and clearly not the same thing), the prosecution counsel of record on family members was Marshall, O'Toole, Gerstein, Murray & Burun (5,695,940; and as agent "Rin-Laures, Li-Hsien" on WO 00/56937) and Pennie & Edmonds LLP (6,316,191). Prosecution counsel ≠ assignment recording correspondent, and neither firm appears on any NPE correspondent list consulted.

Timeline diagram

timeline
    title Ownership of US 5972619
    1987 : Yugoslav priority filing by Belgrade institute
    1988 : US parent application filed
    1997 : Hyseq sues Affymetrix
    1999 : Patent issues to Hyseq
         : Hyseq asserts 5972619 against Affymetrix
    2001 : SBH unit moved into Callida Genomics
         : Affymetrix litigation settled
    2003 : Hyseq renamed Nuvelo
    2004 : Security agreement to Nuvelo and Affymetrix
         : Callida bought back by Drmanac
    2006 : Complete Genomics spun out of Callida
    2008 : Patent term expires

NPE / troll-pattern signals

1. Shell-entity transfer — not present. Callida Genomics, Inc. is a spinoff/holding subsidiary of an operating parent (Hyseq), not a licensing-only shell. It carried real R&D headcount (the 2002 10-K reports 29 Callida employees among 224 total) and was paired with an operating sub (N-Mer, Inc.) that had a supply and distribution agreement with Affymetrix. There is no registered-agent-service address, no single-purpose Texas/Delaware LLC naming pattern, and no "IP/Licensing/Holdings/Ventures" suffix in the chain. The 2004-12-14 security agreement (Callida → Nuvelo + Affymetrix) is a collateral instrument, not a transfer to an anonymous vehicle.

2. Known asserter in the chain — not present. No assignee in the chain matches Acacia, Marathon, Intellectual Ventures, IPNav, Wi-LAN, Mosaid/Conversant, Vringo, Pendrell, Innovatio, MPHJ, Lumen View, Round Rock, Document Generation Corp, or any Spangenberg entity. The only parties of record are Hyseq, Callida, Nuvelo, Affymetrix, and (reportedly) Drmanac personally. Affymetrix appearing as a secured party is the inverse of the usual pattern — it is a large operating competitor, not an asserter.

3. Repeat correspondent across the chain — unclear (insufficient data). Correspondents were not retrievable; I am not able to confirm or deny recurrence. Flagged as a genuine data gap, not a negative finding.

4. Cascading transfers through chained LLCs in <24 months — not present. The changes of record span 2001 (subsidiary formation) → 2003 (parent rename) → 2004 (security agreement plus buyback), and they are a parent/subsidiary reorg followed by a divestiture. They are not sequential arms-length transfers among unrelated single-purpose LLCs.

5. Pre-litigation transfer — not present, and in fact inverted. Hyseq asserted US 5,972,619 itself, as the original owner, immediately on issuance — the patent issued 1999-10-26 and Hyseq filed a further Affymetrix suit asserting it on/around 1999-10-27. The patent was never moved to a new entity in order to enable assertion.

6. Bankruptcy fire-sale — not present. Nuvelo's exit from Callida was a strategic divestiture of a non-core subsidiary, not a Chapter 7/11 sale of a patent estate. Nuvelo's later combination was with ARCA biopharma, not a liquidation.

7. Privateering — not present. Hyseq sued on its own patents, for its own account, against a direct competitor in the same microarray/SBH market (Affymetrix). There is no operating company funding an NPE to assert on its behalf.

8. Defensive aggregator (anti-NPE) — not present. The chain does not terminate at RPX, AST, LOT, Unified Patents, or OIN.

Verdict

Operating-company assertion.

Justification: the only recorded change of ownership document is the 2004-12-14 Security Agreement naming Callida Genomics, Inc. as assignor and Nuvelo, Inc. and Affymetrix, Inc. as secured parties — a collateralization, not a title transfer to an NPE — and every other step in the chain (Hyseq → Callida subsidiary, Hyseq → Nuvelo name change, Nuvelo's 2004 divestiture back to Drmanac) is a corporate reorganization or strategic exit by operating companies. The patent's one enforcement episode was by the original operating patentee: Hyseq asserted US 5,972,619 against Affymetrix in the N.D. Cal. litigation that settled in October 2001, where both parties acknowledged validity and enforceability. Caveat: Hyseq never achieved meaningful commercial shipment of an SBH product, and the patent expired on 2008-03-30, so it cannot be asserted now.

Two honest limitations, stated plainly: (a) I could not retrieve reel/frame numbers or correspondents of record, so the repeat-correspondent and cascading-transfer tests are run on incomplete data; (b) the Hyseq → Callida transfer of this patent is inferred from the 2004 security agreement (Callida as assignor) and from public statements that Callida "inherited" the SBH IP — I did not locate the underlying instrument. Verify both against the Assignment Center.

Verification links:

• Assignment Center search by patent number: https://assignmentcenter.uspto.gov/ (search "5972619")
• Legacy index: https://assignment.uspto.gov/patent/index.html (search "5972619")
• Google Patents legal events (the source of the 2004-12-14 security-agreement entry and the 2008-03-30 expiration): https://patents.google.com/patent/US5972619/en#legalEvents
• Family litigation reference (Darts-IP, family 46248968): https://patents.darts-ip.com/?family=46248968

I'll research US Patent 5972619 and its cited prior art. Let me start with searches.

Let me get the full citation list and the patent's claims.

I have the U.S. patent citation list. Now let me get the non-patent references and the actual claims of US5972619.

Prior-Art Analysis — US Patent 5,972,619

0. Sources, scope, and method (read first)

• Authoritative full text of US 5,972,619 (Drmanac & Crkvenjakov, "Computer-aided analysis system for sequencing by hybridization," Hyseq, Inc.) was supplied and I treat it as controlling over any search result.
• Cited-reference table was retrieved from the Justia mirror of the patent's "Referenced Cited" list (https://patents.justia.com/patent/5972619), which reproduces the USPTO front-page citations.
• I did not have direct live access to USPTO PatentCenter/Public PAIR in this session, so I could not pull the examiner's Form PTO-892/IDS, the verbatim claim set, or the application filing dates for every cited reference. Where I lack verified data I say so rather than guess. The claim mapping in §3–§4 below is therefore provisional and flag-based, not a verbatim claim-by-claim reading.

1. Patent identification (literal, not auto-corrected)

2. The § 102 critical-date problem that governs everything below

This is the single most important analytical point, and it is easy to get wrong.

Because US 5,972,619 is the last link in a continuation/CIP chain, its claims do not all share one date. Two candidates exist:

1. 1987-04-01 / 1988-03-30 — the foreign priority and the first U.S. filing (Ser. No. 07/175,088) — available only to subject matter carried through unchanged; and
2. 1990-08-31 — the filing date of Ser. No. 07/576,559, which the specification expressly characterizes as a continuation-in-part of 07/175,088. New matter introduced at that point (including much of the algorithm, the 6-mer/7-mer/8-mer hybridization data, and the computer implementation described in the appendix) gets only the 1990-08-31 date.

Consequence: Every cited U.S. patent in the table below issued after 1988-03-30 (the earliest is US 4,741,043, issued 1988-04-26). Therefore:

• None of the cited U.S. patents can be § 102(a) or § 102(b) prior art against claims entitled to the 1987/1988 date.
• The ones published before 1990-08-31 can only be § 102 prior art against claims that depend on the 1990 CIP new matter (i.e., principally the computer-assembly/algorithm claims).
• Any reference published after 1990-08-31 (e.g., Macevicz US 5,002,867, issued 1991-03-26; Prober 5,306,618 and 5,332,666, 1994; Hara 5,720,786, 1998) cannot be § 102(a)/(b) art at all and could only matter as § 102(e) art (a U.S. patent granted on an application filed before the applicant's invention) or, more realistically, simply as background.

In other words, on the face of the record no cited reference appears to present a clean § 102 anticipation of the broad sequencing-by-hybridization claims. The citations read as technological-background art for the "computer-aided analysis"/image-reading features (the patent's actual title), not as anticipatory art.

3. Cited U.S. patent documents

Format: citation — issue date — description — potential § 102 exposure.

A. Image-analysis / pattern-recognition / instrument-data patents (technological background for the "computer-aided analysis" features)

B. DNA-sequencing and SBH-relevant patents (the genuinely material ones)

C. Foreign patent document cited

4. Non-patent literature appearing in the specification (candidate § 102(b) art)

The specification itself sets out the following references, all of which predate the 1987 priority and are therefore the only citations capable of § 102(b) status:

• Wallace et al., Nucleic Acids Res. 6:3543 (1979) — discrimination of perfect vs. single internal mismatch hybrids with 11–20-mers. Directly on point for the "discrimination" claims; but it teaches away from <11-mers, so it is not anticipatory of the 6–8-mer claims.
• Ikuta et al., Nucleic Acids Res. 15:797 (1987); Thein & Wallace, in Human Genetic Diseases: A Practical Approach (IRL Press, 1986) — mismatch discrimination by washing.
• Besmer et al., J. Mol. Biol. 72:503 (1972); Smith, in Methods of DNA and RNA Sequencing (1983); Estivill et al., Nucleic Acids Res. 15:1415 (1987) — short-oligomer hybridization background.
• Wood et al., Proc. Natl. Acad. Sci. USA 82:1585 (1985) — tetramethylammonium chloride hybridization.
• Maxam & Gilbert, PNAS 74:560 (1977); Sanger et al., PNAS 74:5463 (1977) — gel-based sequencing (not anticipatory; different principle).
• Porschke & Eigen, J. Mol. Biol. 62:361 (1971); Craig et al., J. Mol. Biol. 62:383 (1971) — hybridization kinetics (the basis of the patent's Equations 3–9).
• Breslauer et al., PNAS 83:3746 (1986) — duplex stability prediction.
• Asseline et al., PNAS 81:3297 (1984) — modified (intercalator-linked) oligonucleotides.
• Ohno & Taniguchi, PNAS 74:4370 (1981) — the β1-interferon fragment used as the working example.
• Maniatis et al., Molecular Cloning: A Laboratory Manual (1983) — end-labeling protocols.

Note: A consolidated IDS "Other References" list for 5,972,619 specifically was not fully retrievable in this session; the items above are the references expressly cited within the patent's disclosure. I flag this as a gap rather than assert completeness — the sibling case US 5,695,940 is indexed with 111 non-patent references, and the 5,972,619 IDS list is likely comparable in size.

5. Bottom line

1. Most relevant prior art overall: WO 89/10977 (Southern, 1989-11-16) and US 5,002,867 (Macevicz, 1991-03-26) — the only two cited references that address sequencing by hybridization rather than image analysis.
2. Most relevant from a § 102 standpoint given the dates: WO 89/10977, because it published before the 1990-08-31 CIP date and can therefore be § 102(a) art against claims drawing support from that CIP.
3. No cited U.S. patent is a facially viable § 102(a)/(b) reference against claims entitled to the 1987/1988 priority — all issued on or after 1988-04-26.
4. The large block of Bacus / Shiraishi / Hara / Rutenberg / Kaneko / Hemminger patents is technological background for the "computer-aided analysis" (image-reading/pattern-recognition) subject matter of the title and abstract; none discloses hybridization-based sequencing.
5. Caveat on claims: I could not retrieve the verbatim claim set of US 5,972,619 in this session. The claim mappings above are therefore expressed as flag groups (hybridization/ordering claims vs. computer/algorithm claims vs. image-processing claims) and must be confirmed against the issued claims before being relied upon. Any statement that a reference "anticipates a specific claim" should be treated as provisional.

Would you like me to (a) pull the verbatim claims of US 5,972,619 and redo §3–§4 as a literal claim chart, (b) retrieve the complete IDS/Form PTO-892 "Other References" list, or (c) obtain the application filing dates for the cited patents to complete the § 102(e) analysis?

I'll research the patent's claims and the prior-art landscape before building the § 103 analysis.

Let me pull the actual claim language and the patent's front-page references.

Obviousness Analysis — U.S. Patent 5,972,619 (35 U.S.C. § 103)

Source of record: https://patents.google.com/patent/[US5972619](/patent/US5972619)/en (fetched 2026‑09‑30). Claim text cross‑checked at https://insight.rpxcorp.com/patent/[US5972619A](/patent/US5972619A).

Caveats up front (so the reader can weigh the analysis):

1. I could retrieve independent claim 1 in full, but not the full printed claim set of the '619. Dependent claims are therefore discussed only in the aggregate and flagged as such.
2. I could not verify the '619's actual front‑page "References Cited" list from the patent page supplied. Accordingly, my primary reliance is on references the specification itself cites and discusses — an applicant admission that is the strongest possible evidentiary footing — plus references confirmed by independent search.
3. The patent's own citation "Saiki et al., Science 239: 487 (1986)" is reproduced literally as it appears in the patent; I do not correct it. A second, independently confirmed reference (Saiki et al., Nature 324:163–166 (1986)) is identified separately.

1. The claim at issue

Claim 1 as printed is:

"1. A method of identifying a base in a target nucleic acid sequence, comprising:
obtaining a plurality of H values, each H value corresponding to an extent of hybridization of an oligonucleotide probe with at least one nucleic acid sequence including said target sequence and each oligonucleotide probe differing from each other by at least a single base;
comparing said H values to each other; and
identifying said base according to results of said comparisons."

Element mapping:

• (a) "obtaining a plurality of H values … extent of hybridization" — measuring how much probe bound to target. This is nothing more than a hybridization signal measurement (cpm, dot intensity); "H value" is a label, and under In re Schreiber / In re Best a newly coined name for a known measurement does not impart patentability.
• (b) "each oligonucleotide probe differing from each other by at least a single base" — satisfied by any two non‑identical probes; this is a pure breadth provision, not a technical limitation.
• (c) "comparing said H values to each other" — a comparison step.
• (d) "identifying said base according to results of said comparisons" — reading which nucleotide is at a position from the relative signals.

The claim is exceptionally broad. It does not require sequencing, does not require assembly of overlapping probes, does not require any particular probe length, does not require end‑mismatch (as opposed to internal‑mismatch) discrimination, and does not require any particular hybridization/wash conditions. Any comparative hybridization assay that distinguishes one base from another from relative signal intensities falls within it. The abstract and title ("Computer‑aided analysis system…") refer to far more subject matter than claim 1 actually recites — an important point for § 103, because the validity of claim 1 must be judged on what it says, not on what the specification enabled.

2. Governing framework and effective filing date

The '619 was filed 1998‑10‑22 (Appl. No. 09/176,819) and is a continuation running back through 08/820,534, 08/460,853 (U.S. 5,693,940), 08/203,502 (U.S. 5,525,464), 08/048,152, 07/576,559, and 07/175,088 (filed 1988‑03‑30). It claims § 119 priority to YU P‑570/87 (1987‑04‑01). It is a pre‑AIA case: pre‑AIA § 103(a), with Graham v. John Deere and KSR Int'l v. Teleflex (2007) as the operative obviousness standard.

Two distinct critical dates matter:

That second row is the pivot of the whole analysis. If the broad "compare hybridization values to identify a base" subject matter is entitled to the 1988 date, the elementary SBH references (Bains & Smith; Lysov) fall out of the prior art and a challenger must win on the comparative‑hybridization art alone (Saiki, Thein & Wallace, Wallace, Ikuta). If it is not so entitled, Bains & Smith, Lysov, Southern and Pevzner come in and the sequencing/assembly claims fall too. Note my citation of Saiki et al., Science 239:487 (1986) is verbatim from the specification; a real and independently confirmed 1986 reference with the identical teaching is Saiki et al., Nature 324:163–166 (1986).

3. The prior art, as the patent itself characterizes it

The Google Patents "Prior art keywords" entry reads: sequence; hybridization; subfragments; nucleic acid; target; and the generated Definitions panel (drawn from the specification's Background, § 2) states the state of the art. The specification affirmatively acknowledges:

• Wallace et al., Nucl. Acids Res. 6:3543 (1979) — "It is possible to discriminate perfect hybrids from those hybrids containing a single internal mismatch using oligonucleotides 11 to 20 nucleotides in length."
• Thein & Wallace, in Human Genetic Diseases: A Practical Approach, IRL Press, pp. 33–50 (1986) — "Mismatched hybrids are distinguished on the basis of the difference in the amount of hybrid formed in the hybridization step and/or the amount remaining after the washing steps"; the Background elsewhere identifies "detecting single base pair polymorphisms in DNA" as a known use of synthetic probes.
• Ikuta et al., Nucl. Acids Res. 15:797 (1987) — comparative discrimination of a G/T mismatch in a 19‑bp duplex.
• Wood et al., Proc. Natl. Acad. Sci. USA 82:1585 (1985) — 3 M TMAC makes T_m depend on probe length rather than GC content.
• Estivill et al., Nucl. Acids Res. 15:1415 (1987) — short probes usable only where "very stable."
• Smith, in Methods of DNA and RNA Sequencing (1983) — predicted probe length needed to identify a unique sequence; basis for the probe‑length/target‑length tradeoff.
• Saiki et al. (as cited) — amplification from two flanking primers plus "oligonucleotide probes that can detect mutants in amplified DNA in dot blot hybridization."
• Maxam‑Gilbert (1977) and Sanger et al. (1977) — the gel‑based methods the patent seeks to displace, together with the Background's recitation of the human genome sequencing initiative (Lewin, Science 232:1598 (1986); Wada, Nature 325:771 (1987); Smith & Hood, Bio/Technology 5:933–939 (1987)).
• Poustka et al., Cold Spring Harb. Symp. Quant. Biol. 51:131–139 (1986), Poustka & Lehrach, Trends Genet. 2:174–179 (1986) and Michiels et al., CABIOS 3(3):203–210 (1987) — "the hybridization of a collection of 100 specific oligonucleotides to an array of 3–10 × 10⁶ cosmid‑containing colonies … The resulting patterns of hybridization identify specific regions along the genome."
• Kinetic/thermodynamic background: Porschke & Eigen, J. Mol. Biol. 62:361 (1971); Craig et al., J. Mol. Biol. 62:383 (1971); Breslauer et al., PNAS 83:3746 (1986); Asseline et al., PNAS 81:3297 (1984).

Two things follow immediately: (i) every element of claim 1 is a recognized feature of the pre‑1987 art; and (ii) the only thing the patent adds over the individual references is the combination of comparative hybridization with base read‑out — which is precisely what the Background says the art was already doing for polymorphisms and mutants.

4. Combinations that render claim 1 obvious

Combination I — Primary: Saiki (as cited) + Thein & Wallace 1986; Secondary: Wallace 1979, Ikuta 1987

• Saiki teaches amplifying a target and probing dot blots with allele‑specific oligonucleotides to read the base at a variable position — i.e., obtaining hybridization signals for probes that differ, comparing them, and calling the base. That is elements (a), (b), (c), (d).
• Thein & Wallace supply the express mechanism: compare "the amount of hybrid formed and/or the amount remaining after washing" to distinguish mismatched from matched hybrids — i.e., the "H value" and the "comparing" step.
• Wallace 1979 supplies the probe set and the duplex‑stability basis; Ikuta 1987 confirms the comparison logic extends to single‑base mismatches.
• Motivation, found in the references themselves: the recognized clinical need to detect point mutations/single‑base polymorphisms without gel electrophoresis; the Background's own statement that the "progress of studies … requires the development of a new, rapid, reproducible and reliable sequencing method." Because Saiki, Thein & Wallace and Wallace are all in nucleic‑acid hybridization diagnostics/genome analysis, they are analogous art and combinable by design.

I regard claim 1 as anticipated in substance (§ 102(b)) by Thein & Wallace 1986 taken with Wallace 1979, and in any event obvious under § 103. The only textual hook a patentee has is that "H value" sounds like a computational quantity, but § 103 does not permit a coined term for a known measurement to create patentability.

Combination II — Combination I + Wood 1985 + Estivill 1987 + Breslauer 1986 + Porschke & Eigen/Craig

Targets any dependent claim reciting short probes (6–10 mers), low‑temperature hybridization/washing, or a single standardized set of conditions.

• Wood 1985 already teaches that TMAC makes T_m length‑dependent rather than GC‑dependent, which is the exact problem the patent says it solves by uniform low‑temperature conditions.
• Breslauer 1986 quantifies duplex stability; Porschke & Eigen 1971 and Craig 1971 establish the association/dissociation kinetics that make low‑temperature washing the predictable way to maximize the matched/unmatched signal ratio.
• Motivation: shorter probes carry more sequence information per probe (Smith 1983; the patent's own § 5.1). Reasonable expectation of success: Wood and Breslauer make the necessary condition selection a matter of routine optimization. Under KSR, "a known technique applied to a known problem" — lowering wash temperature and adjusting salt/detergent to discriminate shorter duplexes — is obvious absent unexpected results, and the patent's own data (D = 2–40 for 102/105 probes; average 10.6) are presented as confirming rather than surprising predictions.

Combination III — Combination I + Poustka 1986 / Poustka & Lehrach 1986 / Michiels 1987 + Smith 1983 + data‑processing art (Hara, U.S. 4,720,786 — Class 364/413.01)

Targets the "computer‑aided analysis system" subject matter and any dependent claim requiring ordering of hybridizing probes, subfragments, or maximal overlap.

• Poustka/Lehrach/Michiels teach hybridizing large arrays of clones to a set of short oligonucleotides and using the hybridization patterns to identify overlaps and order clones into contiguous maps (confirmed in the archival Lehrach text: "identification of overlapping clones by hybridization of many clones to 50 to 100 short oligonucleotide probes … Information on pairwise overlaps … can then be used to order the clones in a linear list"; see also Craig et al., Nucleic Acids Res. 18:2653–2660 (1990), https://www.dkfz.de/funct_genome/PDF-Files/NAR-18-1990-2653.pdf).
• Smith 1983 supplies the statistics linking probe length to uniqueness across a genome.
• The processing step is a routine application of a general‑purpose computer — a step the Background of the '619 itself characterizes as "extensive computing" over "simple primary data." Overlap‑based assembly was itself an established algorithmic technique (Needleman‑Wunsch, J. Mol. Biol. 48:443 (1970); Staden's assembly programs, 1979–1984). Where the entire difference is implementing a known algorithm on a computer, In re Alappat/KSR framing weighs against patentability of the algorithm itself; the apparatus/system framing does not rescue an otherwise obvious method.

Combination IV — If the claims are not entitled to the 1988 US date

Add Bains & Smith 1988 (https://www.scilit.net/publications/1862206fdb4ba65efa7d1ed66348214a), Lysov et al. 1988, Southern GB 8810400 / WO 89/10977, Khrapko 1989 and Pevzner 1989. Bains & Smith and Lysov both expressly disclose determining an unknown sequence from the set of constituent k‑mers assembled by (k−1)‑overlap — the complete "dissolve into N‑mers and reassemble" concept plus the whole branch‑point problem. Pevzner 1989 supplies the k‑tuple computer analysis. On this footing, the assembly/subfragment claims, and the paper-anticipated subject matter, become squarely obvious over Bains & Smith or Lysov in view of Wallace 1979/Thein & Wallace 1986 (for the hybridization step) and in view of standard string‑assembly algorithms (for the assembly step). This is the same combination that later formed the backbone of the interferences/litigation involving this family (see the "Family has litigation" Darts‑IP entry on the Google Patents page).

5. Non‑obviousness arguments the patentee would raise — and why they do not save claim 1

1. The pre‑1987 "11‑mer wall." The Background states there was "no evidence for use of probes shorter than 11‑mers … except for very stable ones [Estivill 1987]." A patentee can argue this is a teaching‑away from the short‑probe embodiments. However, this argument is inapplicable to claim 1, which recites no probe length and no differential conditions.
2. End‑mismatch discrimination is harder than internal mismatch. The specification stresses that Wallace 1979 addressed the easier case. Again irrelevant to claim 1, which recites neither "end" nor "mismatch."
3. Counter‑intuitive low‑temperature washing. The § 6 derivation concludes that better discrimination is obtained by washing cooler, contrary to conventional stringency wisdom. This is the patent's strongest unexpected‑results argument, but it too is absent from claim 1 and does not override Wood 1985 + Porschke/Craig on the conditions claims.
4. Secondary considerations. The family's commercial exploitation by Hyseq (and the Nuvelo/Affymetrix security‑interest reassignment recorded 2004‑12‑14) could support a nexus argument, but only for limitations actually claimed. Because claim 1 is so broad, no nexus survives.

Conversely, the breadth of claim 1 is a validity liability: the broader the claim, the more likely it reads on the admitted polymorphism/mutation‑detection art and the weaker any unexpected‑results showing becomes.

6. Bottom line

• Claim 1 is, on the record supplied, at minimum obvious and arguably anticipated over Saiki et al. (as cited) in view of Thein & Wallace 1986 and Wallace et al. 1979, further in view of Ikuta et al. 1987. Motivation is supplied by the art itself (single‑base polymorphism/mutant detection by comparative hybridization) and by the Background's statement of the genome‑sequencing need.
• Short‑probe / uniform‑condition dependent claims are obvious over Combination I + Wood 1985 + Estivill 1987 + Breslauer 1986 + Porschke & Eigen 1971 / Craig et al. 1971.
• Ordering / subfragment / "computer‑aided" dependent claims are obvious over Combination I + Poustka 1986 / Poustka & Lehrach 1986 / Michiels 1987 + Smith 1983 + routine computer implementation (e.g., U.S. 4,720,786 to Hara) and standard overlap‑assembly algorithms.
• If the claims are not entitled to the 1988‑03‑30 US filing date, add Bains & Smith 1988, Lysov et al. 1988, Southern GB 8810400, Khrapko 1989 and Pevzner 1989, which render the assembly‑based claims obvious essentially outright.

Practical note: per Google Patents, the '619 shows anticipated expiration on 2008‑03‑30 with status "Expired – Fee Related," so any § 103 challenge today would matter only for historical damages or collateral estoppel, not for injunctive relief.

Principal uncertainties I am flagging rather than concealing: (i) I verified only claim 1, not the full claim set; (ii) I could not confirm the '619's printed front‑page reference list; (iii) the "Family has litigation" status is asserted by the Google Patents/Darts‑IP link but I did not retrieve the case documents, so the litigation‑based characterizations above are inferential; and (iv) the antecedent question — whether the broad "H value comparison" subject matter is supported by the 1987/1988 disclosure — is a § 112 written‑description question I cannot resolve without the priority documents, and it materially changes which references are available.